**Product:** Exjade  
**Generic Name:** deferasirox  
**Manufacturer:** Novartis Pharmaceuticals Canada Inc.

**Date Submission Received:** 2006-Oct-26  
**Date NOC Issued:** 2006-Oct-18

**Priority Review Granted:** Denied

**Targeted CEDAC Meeting:** 2007-Mar-21

<table>
<thead>
<tr>
<th>Phase</th>
<th>Target Time (Business Days)</th>
<th>Target Date**</th>
<th>Actual CDR Date</th>
<th>Comments</th>
</tr>
</thead>
</table>
| 2     | CDR Reviewers' Reports Completed  
- Reviewers selected and contracted  
- Literature search and selection completed  
- Systematic review of clinical data completed  
- Critical appraisal of pharmacoeconomic (PE) data completed  
- Clinical and PE reports written  
- Reports edited and finalized  
| 3     | Comments from Manufacturer on Reviewers' Reports Received by CDR | 7             | 2007-Feb-09     | 2007-Feb-14 | Due date for manufacturer's comments February 14, 2007. |
| 5     | CEDAC Brief Completed and Sent to CEDAC Members | 5             | 2007-Mar-07     | 2007-Mar-07 | |
| 6     | CEDAC Meeting | | 2007-Mar-21 | 2007-Mar-21 | |
| 8     | Embargo Period***  
Manufacturers may make a Request for Reconsideration and Drug Plans may make a Request for Clarification of the Recommendation and Reasons for Recommendation | 10            | 2007-Apr-12     | 2007-Apr-12 | |
| 9 (a) | Final Recommendation sent to Drug Plans, ACP, and Manufacturer  
(No Requests for Clarification are made AND no Request for Reconsideration is made or Request for Reconsideration is Resolved) | 5             | 2007-Apr-19     | 2007-Apr-19 | Notice of Final Recommendation issued. |
| OR    | 9 (b) | Clariification and Final Recommendation sent to Drug Plans, ACP, and Manufacturer  
(Clariification Requested, no Request for Reconsideration made) | 5             | | |
| OR    | 9 (c) | Placed on CEDAC Agenda For Reconsideration (At Manufacturer's request) | 25            | Depends on Meeting Dates | |
| 10    | Final Recommendation sent to Drug Plans, ACP, and Manufacturer | | | 5 |

---

* Refer to the Procedure for Common Drug Review on the Common Drug Review section of www.cadth.ca for more details.  
** The CDR review process is initiated AFTER a submission is deemed complete. The target dates for this report are based on the CEDAC meeting schedule, which is posted on www.cadth.ca.  
*** The Recommendation and Reasons for Recommendation are to be held in confidence and not acted upon until after the CDR Directorate has issued the notice of Final Recommendation.